The clinical potential of targeted nanomedicine: Delivering to cancer stem-like cells

Molecular Therapy

Volumn 22, Issue 2, 2014, Pages 278-291

  Kim, Sang Soo ^a   Rait, Antonina ^a   Rubab, Farwah ^b   Rao, Abhi K ^a   Kiritsy, Michael C ^a   Pirollo, Kathleen F ^a   Wang, Shangzi ^a   Weiner, Louis M ^a   Chang, Esther H ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b SynerGene Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; BIOLOGICAL MARKER; CD133 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; GREEN FLUORESCENT PROTEIN; HERMES ANTIGEN; NANOPARTICLE; NESTIN; OLIGONUCLEOTIDE; P53 PROTEIN ANTIBODY; PLASMID DNA; PROTEIN ANTIBODY; PROTEIN MSI1; PROTEIN P53; STAGE SPECIFIC EMBRYO ANTIGEN 1; TRANSCRIPTION FACTOR NANOG; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; LIPOSOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BRAIN CANCER; CANCER INHIBITION; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; CELL DEATH; CELL DIFFERENTIATION; CELL TRANSPORT; CELLULAR DISTRIBUTION; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE; GENE DELIVERY SYSTEM; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOLECULARLY TARGETED THERAPY; MOUSE; NANOMEDICINE; NONHUMAN; OUTCOME ASSESSMENT; TRANSGENE; TUMOR XENOGRAFT; WTP53 GENE; ANIMAL; ANTIBODY SPECIFICITY; BRAIN; CELL SURVIVAL; COLORECTAL NEOPLASMS; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG SCREENING; GENE EXPRESSION; GENE TRANSFER; GENETICS; IMMUNOPHENOTYPING; METABOLISM; NEOPLASMS; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALIA;

ANIMALS; APOPTOSIS; BRAIN; CELL LINE, TUMOR; CELL SURVIVAL; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FEMALE; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; HUMANS; IMMUNOPHENOTYPING; LIPOSOMES; MICE; NANOMEDICINE; NEOPLASMS; NEOPLASTIC STEM CELLS; ORGAN SPECIFICITY; RECEPTORS, TRANSFERRIN; TRANSGENES; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84895902330     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.231     Document Type: Article

References (50)

1. Visvader, JE and Lindeman, GJ (2008). Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8: 755-768.
2. Park, CY, Tseng, D and Weissman, IL (2009). Cancer stem cell-directed therapies: recent data from the laboratory and clinic. Mol Ther 17: 219-230.
3. Bonnet, D and Dick, JE (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730-737.
4. Al-Hajj, M, Wicha, MS, Benito-Hernandez, A, Morrison, SJ and Clarke, MF (2003). Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988.
5. Singh, SK, Hawkins, C, Clarke, ID, Squire, JA, Bayani, J, Hide, T et al. (2004). Identification of human brain tumour initiating cells. Nature 432: 396-401.
6. O'Brien, CA, Pollett, A, Gallinger, S and Dick, JE (2007). A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106-110.
7. Kim, CF, Jackson, EL, Woolfenden, AE, Lawrence, S, Babar, I, Vogel, S et al. (2005). Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121: 823-835.
8. Collins, AT, Berry, PA, Hyde, C, Stower, MJ and Maitland, NJ (2005). Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946- 10951.
9. Arap, W, Pasqualini, R and Ruoslahti, E (1998). Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279: 377-380.
10. Sugahara, KN, Teesalu, T, Karmali, PP, Kotamraju, VR, Agemy, L, Girard, OM et al. (2009). Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 16: 510-520.
11. Chen, Y, Wu, JJ and Huang, L (2010). Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy. Mol Ther 18: 828-834.
12. Low, PS and Kularatne, SA (2009). Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol 13: 256-262.
13. Cheng, PW (1996). Receptor ligand-facilitated gene transfer: enhancement of liposome-mediated gene transfer and expression by transferrin. Hum Gene Ther 7: 275-282.
14. Xu, L, Pirollo, KF, Tang, WH, Rait, A and Chang, EH (1999). Transferrin-liposomemediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts. Hum Gene Ther 10: 2941-2952.
15. Bartlett, DW, Su, H, Hildebrandt, IJ, Weber, WA and Davis, ME (2007). Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci USA 104: 15549- 15554.
16. Park, JW, Hong, K, Kirpotin, DB, Colbern, G, Shalaby, R, Baselga, J et al. (2002). Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 8: 1172-1181.
17. Xu, L, Tang, WH, Huang, CC, Alexander, W, Xiang, LM, Pirollo, KF et al. (2001). Systemic p53 gene therapy of cancer with immunolipoplexes targeted by antitransferrin receptor scFv. Mol Med 7: 723-734.
18. Xu, L, Huang, CC, Huang, W, Tang, WH, Rait, A, Yin, YZ et al. (2002). Systemic tumortargeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol Cancer Ther 1: 337-346.
19. Farokhzad, OC, Cheng, J, Teply, BA, Sherifi, I, Jon, S, Kantoff, PW et al. (2006). Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 103: 6315-6320.
20. Hwang, SH, Rait A, Pirollo KF, Zhou Q, Yenugonda VM, Chinigo, GM et al. (2008). Tumortargeting nanodelivery enhances the anticancer activity of a novel quinazolinone analogue. Mol Cancer Ther 7: 559-568.
21. Pirollo, KF, Rait, A, Zhou, Q, Hwang, SH, Dagata, JA, Zon, G et al. (2007). Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. Cancer Res 67: 2938-2943.
22. Pirollo, KF, Zon, G, Rait, A, Zhou, Q, Yu, W, Hogrefe, R et al. (2006). Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery. Hum Gene Ther 17: 117-124.
23. Pirollo, KF, Rait, A, Zhou, Q, Zhang, XQ, Zhou, J, Kim, CS et al. (2008). Tumor-targeting nanocomplex delivery of novel tumor suppressor RB94 chemosensitizes bladder carcinoma cells in vitro and in vivo. Clin Cancer Res 14: 2190-2198.
24. Rait, AS, Pirollo, KF, Xiang, L, Ulick, D and Chang, EH (2002). Tumor-targeting, systemically delivered antisense HER-2 chemosensitizes human breast cancer xenografts irrespective of HER-2 levels. Mol Med 8: 475-486.
25. Xu, L, Frederik, P, Pirollo, KF, Tang, WH, Rait, A, Xiang, LM et al. (2002). Self-assembly of a virus-mimicking nanostructure system for efficient tumor-targeted gene delivery. Hum Gene Ther 13: 469-481.
26. Daniels, TR, Bernabeu, E, Rodruez, JA, Patel, S, Kozman, M, Chiappetta, DA et al. (2012). The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta 1820: 291-317.
27. Senzer, N, Nemunaitis, J, Nemunaitis, D, Bedell, C, Edelman, G, Barve, M et al. (2013). Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors. Mol Ther 21: 1096-1103.
28. Boyd, SD, Tsai, KY and Jacks, T (2000). An intact HDM2 RING-finger domain is required for nuclear exclusion of p53. Nat Cell Biol 2: 563-568.
29. Fang, J, Nakamura, H and Maeda, H (2011). The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 63: 136-151.
30. Ailles, LE and Weissman, IL (2007). Cancer stem cells in solid tumors. Curr Opin Biotechnol 18: 460-466.
31. Duru, N, Fan, M, Candas, D, Menaa, C, Liu, HC, Nantajit, D et al. (2012). HER2- associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells. Clin Cancer Res 18: 6634-6647.
32. Jordan, CT (2009). Cancer stem cells: controversial or just misunderstood? Cell Stem Cell 4: 203-205.
33. Jin, L, Hope, KJ, Zhai, Q, Smadja-Joffe, F and Dick, JE (2006). Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12: 1167-1174.
34. Beier, D, Schulz, JB and Beier, CP (2011). Chemoresistance of glioblastoma cancer stem cells-much more complex than expected. Mol Cancer 10: 128.
35. Harris, CC (1996). Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 88: 1442-1455.
36. Li, H, Lochmler, H, Yong, VW, Karpati, G and Nalbantoglu, J (1997). Adenovirusmediated wild-type p53 gene transfer and overexpression induces apoptosis of human glioma cells independent of endogenous p53 status. J Neuropathol Exp Neurol 56: 872-878.
37. Yu, W, Pirollo, KF, Yu, B, Rait, A, Xiang, L, Huang, W et al. (2004). Enhanced transfection efficiency of a systemically delivered tumor-targeting immunolipoplex by inclusion of a pH-sensitive histidylated oligolysine peptide. Nucleic Acids Res 32: e48.
38. Freedman, M, Chang, EH, Zhou, Q and Pirollo, KF (2009). Nanodelivery of MRI contrast agent enhances sensitivity of detection of lung cancer metastases. Acad Radiol 16: 627-637.
39. Pirollo, KF, Dagata, J, Wang, P, Freedman, M, Vladar, A, Fricke, S et al. (2006). A tumor-targeted nanodelivery system to improve early MRI detection of cancer. Mol Imaging 5: 41-52.
40. Yang, C, Rait, A, Pirollo, KF, Dagata, JA, Farkas, N and Chang, EH (2008). Nanoimmunoliposome delivery of superparamagnetic iron oxide markedly enhances targeting and uptake in human cancer cells in vitro and in vivo. Nanomedicine 4: 318-329.
41. Pannuti, A, Foreman, K, Rizzo, P, Osipo, C, Golde, T, Osborne, B et al. (2010). Targeting Notch to target cancer stem cells. Clin Cancer Res 16: 3141-3152.
42. Dodge, ME and Lum, L (2011). Drugging the cancer stem cell compartment: lessons learned from the hedgehog and Wnt signal transduction pathways. Annu Rev Pharmacol Toxicol 51: 289-310.
43. Shan, J, Shen, J, Liu, L, Xia, F, Xu, C, Duan, G et al. (2012). Nanog regulates selfrenewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma. Hepatology 56: 1004-1014.
44. Clement, V, Sanchez, P, de Tribolet, N, Radovanovic, I and Ruiz i Altaba, A (2007). HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell selfrenewal, and tumorigenicity. Curr Biol 17: 165-172.
45. Lonardo, E, Frias-Aldeguer, J, Hermann, PC and Heeschen, C (2012). Pancreatic stellate cells form a niche for cancer stem cells and promote their self-renewal and invasiveness. Cell Cycle 11: 1282-1290.
46. LaBarge, MA (2010). The difficulty of targeting cancer stem cell niches. Clin Cancer Res 16: 3121-3129.
47. Lombardo, Y, Scopelliti, A, Cammareri, P, Todaro, M, Iovino, F, Ricci-Vitiani, L et al. (2011). Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice. Gastroenterology 140: 297-309.
48. Todaro, M, Alea, MP, Di Stefano, AB, Cammareri, P, Vermeulen, L, Iovino, F et al. (2007). Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 1: 389-402.
49. Hadjipanayis, CG, Fellows-Mayle, W and Deluca, NA (2008). Therapeutic efficacy of a herpes simplex virus with radiation or temozolomide for intracranial glioblastoma after convection-enhanced delivery. Mol Ther 16: 1783-1788.
50. Conaway, CC, Wang, CX, Pittman, B, Yang, YM, Schwartz, JE, Tian, D et al. (2005). Phenethyl isothiocyanate and sulforaphane and their N-acetylcysteine conjugates inhibit malignant progression of lung adenomas induced by tobacco carcinogens in A/J mice. Cancer Res 65: 8548-8557.